Resources

Blood Viscosity & Cardiovascular Disease: What the Evidence Shows

Blood Viscosity & Cardiovascular Disease: What the Evidence Shows

Atherosclerosis • Stroke & MI risk • Why whole blood viscosity belongs in preventive care

Blood viscosity (WBV)—how thick and sticky blood is—may be one of the most important, under-recognized drivers of cardiovascular risk. Multiple cohorts and mechanistic reports suggest WBV can equal or exceed traditional markers in predicting heart attack, stroke, and atherosclerosis.

Key idea: Viscosity acts upstream of many risks—affecting shear stress, endothelial injury, microcirculatory flow, and ultimately event rates.

The Edinburgh Artery Study: Five-Year Prospective Evidence

Show Section

In a community cohort of 1,592 adults (55–74 yrs), participants who experienced cardiovascular events had significantly higher WBV than those who did not (p=0.0003). Predictive strength of WBV was comparable to LDL cholesterol and diastolic blood pressure, and stronger than smoking—all established risks.[1]

A Unifying Mechanism Linking Major Risk Factors

Show Section

Dr. Gregory Sloop proposed WBV as a central pathway through which diverse risks—lipids, hypertension, diabetes, obesity, smoking—converge on atherosclerosis.[2] The framework helps explain:

  • Why lesion patterns look similar across different risk profiles
  • How turbulent flow and high shear activate platelets
  • Why HDL appears protective (it can lower viscosity)

Bottom line: Monitoring WBV offers a single, measurable window on multi-factor vascular stress.

Risk Factors Consistently Associated with Higher WBV

Show Section
Selected Associations Between WBV and Cardiometabolic Risks
Risk Category Examples / Notes Refs
Hypertension Direct, graded relationships; rheological determinants of BP [3–6]
Lipids High LDL, high triglycerides, and low HDL associate with higher WBV [7–13]
Metabolic Type 2 diabetes, insulin resistance, obesity [12,14–18]
Smoking Synergistic with hypertension for hyperviscosity [6,19–21]
Sex & Age Higher in men vs. premenopausal women; rises with aging [12–13,22–24]

Note: Hematocrit contributes to WBV, but it isn’t the whole story. Plasma proteins (e.g., fibrinogen), RBC aggregation, and deformability strongly influence viscosity—especially at low shear (diastolic) conditions.

Why Measure Both Systolic and Diastolic Viscosity?

Show Section

Like blood pressure, WBV changes every heartbeat. Systolic WBV reflects high-shear flow; diastolic WBV reflects low-shear microcirculation where RBC aggregation and plasma proteins dominate.

  • Pressure vs. viscosity: BP measures force in the vessel; WBV measures the condition of the blood. Viscosity can rise before BP and sustain vascular strain.
  • Clinical utility: Earlier signal for endothelial stress, microvascular hypoperfusion, and thrombotic tendency.

About MVL’s Whole Blood Viscosity Profile

Show Section
  • Method: Calibrated glass capillary system (direct whole-blood behavior)
  • Regulatory: FDA Class I device (21 CFR § 862.2920)
  • Outputs: Systolic and diastolic WBV
  • Billing: Not covered by insurance; providers bill patients directly

Clinical Implications & Next Steps

Show Section
  • Identify silent risk in patients with “normal” standard panels
  • Guide interventions: hydration/electrolytes, omega-3s, anti-inflammatory nutrition, triglyceride control, fibrinogen management, activity
  • Use pre/post WBV testing to confirm benefit and personalize care

Important Interpretation Notes

Measured parameter, not diagnosis: MVL reports whole blood viscosity to inform clinical decision-making. Results must be interpreted by licensed clinicians alongside history, exam, and other labs.

Ready to Add Viscosity to Your CV Risk Workflow?

Show Section

Practitioners: Contact Client Services to order or discuss interpretation.

Patients: Speak with your licensed provider. Meridian Valley Lab provides laboratory services only and cannot advise patients directly.

Call: 855.405.8378 | 206.209.4200

References

Show References
  1. Lowe GD, Lee AJ, Rumley A, et al. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168–173.
  2. Sloop GD. A unifying theory of atherogenesis. Med Hypotheses. 1996;47:321–5.
  3. Smith WC, Lowe GD, et al. Rheological determinants of blood pressure in a Scottish adult population. J Hypertens. 1992;10:467–72.
  4. Letcher RL, Chien S, et al. Direct relationship between blood pressure and blood viscosity. Am J Med. 1981;70:1195–1202.
  5. Devereux RB, Case DB, Alderman MH, et al. Blood viscosity in systemic hypertension. Am J Cardiol. 2000;85:1265–1268.
  6. Levenson J, Simon AC, et al. Smoking, hypertension, and blood hyperviscosity. Arteriosclerosis. 1987;7:572–577.
  7. 7–24. See full list in the original document.